NCT05463757View on ClinicalTrials.gov

Oral Hedgehog Inhibitors in the Treatment of Basal Cell Carcinoma in the Netherlands: a Prospective Registration Study

RecruitingOBSERVATIONAL
Enrollment

80

Participants

Timeline

Start Date

November 1, 2021

Primary Completion Date

June 30, 2026

Study Completion Date

December 31, 2026

Conditions
Basal Cell CarcinomaLocally Advanced Basal Cell CarcinomaMetastatic Basal Cell CarcinomaGorlin SyndromeBasal Cell Nevus SyndromeCarcinoma, Basal CellCarcinomaBasal Cell TumorSkin CancerNeoplasm of SkinNeoplasms, Basal Cell
Interventions
DRUG

Vismodegib

Oral vismodegib (Erivedge), taken daily or every other day (depending on doctor's description)

DRUG

Sonidegib

Sonidegib (Odomzo), taken daily or every other day (depending on doctor's description)

Trial Locations (8)

Unknown

RECRUITING

Radboudumc, Nijmegen

RECRUITING

Maastricht University Medical Center +, Maastricht

RECRUITING

Amsterdam UMC, Amsterdam

RECRUITING

Netherlands Cancer Institute - AVL, Amsterdam

NOT_YET_RECRUITING

UMCG, Groningen

RECRUITING

LUMC, Leiden

RECRUITING

Erasmus MC, Rotterdam

RECRUITING

UMC Utrecht, Utrecht

All Listed Sponsors
collaborator

Sun Pharmaceutical Industries Limited

INDUSTRY

lead

Maastricht University Medical Center

OTHER